Affinity Asset Advisors LLC Sells 2,000 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Affinity Asset Advisors LLC decreased its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 7.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,000 shares of the company’s stock after selling 2,000 shares during the period. Affinity Asset Advisors LLC’s holdings in SpringWorks Therapeutics were worth $2,060,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SWTX. Perceptive Advisors LLC grew its holdings in SpringWorks Therapeutics by 16.1% during the 1st quarter. Perceptive Advisors LLC now owns 4,849,912 shares of the company’s stock valued at $356,808,000 after buying an additional 672,191 shares in the last quarter. BlackRock Inc. grew its holdings in SpringWorks Therapeutics by 9.6% during the 2nd quarter. BlackRock Inc. now owns 2,486,323 shares of the company’s stock valued at $204,897,000 after buying an additional 216,785 shares in the last quarter. Vanguard Group Inc. grew its holdings in SpringWorks Therapeutics by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 2,706,067 shares of the company’s stock valued at $223,007,000 after buying an additional 212,011 shares in the last quarter. FMR LLC grew its holdings in SpringWorks Therapeutics by 4.7% during the 2nd quarter. FMR LLC now owns 3,968,220 shares of the company’s stock valued at $327,021,000 after buying an additional 176,852 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in SpringWorks Therapeutics by 69.5% during the 2nd quarter. Jennison Associates LLC now owns 313,659 shares of the company’s stock valued at $25,849,000 after buying an additional 128,574 shares in the last quarter. Institutional investors own 90.00% of the company’s stock.

In other news, major shareholder Bain Capital Life Sciences Inv sold 1,000,000 shares of SpringWorks Therapeutics stock in a transaction on Tuesday, August 10th. The stock was sold at an average price of $70.25, for a total transaction of $70,250,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider L. Mary Smith sold 10,000 shares of SpringWorks Therapeutics stock in a transaction on Wednesday, October 13th. The stock was sold at an average price of $55.97, for a total value of $559,700.00. The disclosure for this sale can be found here. Insiders have sold 1,053,928 shares of company stock valued at $74,152,182 over the last ninety days. 30.76% of the stock is owned by insiders.

A number of equities research analysts have issued reports on SWTX shares. HC Wainwright increased their price objective on shares of SpringWorks Therapeutics from $136.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 5th. Zacks Investment Research raised shares of SpringWorks Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 29th. JPMorgan Chase & Co. raised their target price on shares of SpringWorks Therapeutics from $97.00 to $105.00 and gave the company an “overweight” rating in a report on Wednesday, September 8th. Finally, The Goldman Sachs Group raised their target price on shares of SpringWorks Therapeutics from $107.00 to $123.00 and gave the company a “buy” rating in a report on Tuesday, July 20th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $113.60.

NASDAQ SWTX traded up $3.78 on Thursday, hitting $60.00. 7,824 shares of the stock were exchanged, compared to its average volume of 293,363. The stock has a fifty day moving average price of $70.34 and a two-hundred day moving average price of $75.15. The firm has a market capitalization of $2.95 billion, a P/E ratio of -32.26 and a beta of 0.66. SpringWorks Therapeutics, Inc. has a 52-week low of $51.57 and a 52-week high of $96.48.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Wednesday, August 4th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.28). During the same period in the prior year, the firm earned ($0.47) EPS. On average, research analysts forecast that SpringWorks Therapeutics, Inc. will post -3.26 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Featured Story: What is Depreciation?

Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX).

Institutional Ownership by Quarter for SpringWorks Therapeutics (NASDAQ:SWTX)

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.